Andrew Blauvelt, Zoe D Draelos, Linda Stein Gold, Javier Alonso-Llamazares, Neal Bhatia, Janet DuBois, Seth B Forman, Melinda Gooderham, Lawrence Green, Scott T Guenthner, Adelaide A Hebert, Edward Lain, Angela Y Moore, Kim A Papp, Matthew Zirwas, Saori Kato, Scott Snyder, David Krupa, Patrick Burnett, David R Berk, David H Chu
BACKGROUND: The topical phosphodiesterase 4 inhibitor roflumilast has been studied in several dermatologic conditions. OBJECTIVE: Roflumilast foam 0.3% is being investigated as a topical treatment for seborrheic dermatitis (SD). METHODS: In this phase 3, double-blinded trial, patients with SD were randomly assigned (2:1 ratio) to once-daily roflumilast foam 0.3% or vehicle foam for 8 weeks. The primary efficacy outcome was Investigator Global Assessment (IGA) Success at week 8, defined as IGA of 0 (Clear) or 1 (Almost Clear) plus ≥2-point improvement from baseline...
January 20, 2024: Journal of the American Academy of Dermatology